Dr. Matthew S. Dietz

Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.

In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs.�

Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

Dr. Dietz is rated as an Advanced provider by MediFind in the treatment of Intersex. His top areas of expertise are Ewing Sarcoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 11 clinical trials in the study of Intersex.